Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study-Reference-Cited by-同舟云学术

Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

Published:2008-10 Issue:15 Volume:44 Page:2169-2177
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Aravantinos Gerasimos,Fountzilas George,Bamias Aristotelis,Grimani Irene,Rizos Spyridon,Kalofonos Haralabos P.,Skarlos Dimosthenis V.,Economopoulos Theofanis,Kosmidis Paris A.,Stathopoulos George P.,Briasoulis Evangelos,Pectasides Dimitrios,Samantas Epaminondas,Timotheadou Eleni,Papadimitriou Christos,Papanikolaou Alexandros,Onyenadum Adimchi,Papakostas Pavlos,Bafaloukos Dimitrios,Dimopoulos Meletios A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer;McGuire;New Engl J Med,1996

2. Chemotherapy of advanced ovarian cancer;McGuire;Sem Oncol,1998

3. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer;Piccart;J Natl Cancer Inst,2000

4. Carboplatin and Paclitaxel in ovarian carcinoma: a phase I study of the gynecologic oncology Group;Bookman;J Clin Oncol,1996

5. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a gynecologic oncology group study;Ozols;J Clin Oncol,2003

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of the Pro-Inflammatory Tumor Microenvironment in Extracellular Vesicle-Mediated Transfer of Therapy Resistance;Frontiers in Oncology;2022-05-11

2. Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline;Current Oncology;2022-01-08

3. Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review;Critical Reviews in Oncology/Hematology;2021-06

4. Ovarian Cancer: Primary Advanced and Recurrent Disease;Practical Medical Oncology Textbook;2021

5. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer;JAMA Network Open;2020-01-10